

Abstract

Mitral transcatheter therapies represent the treatment of choice for all patients deemed unsuitable for cardiac surgery. So far, the largest clinical experience has been limited to percutaneous repair techniques. However, given the complexity and heterogeneity of mitral valve anatomy and pathology, transcatheter mitral valve implantation (TMVI) will widen the mitral valve therapies horizon, toward a patient-tailored approach. Current data about TMVI is still limited and, although some data are promising, there are still some issues to be addressed.

The following lecture provides a comprehensive insight of the available devices and describes potential advantages and limitations of TMVI.